Peer-reviewed veterinary case report
Biomarkers for detecting mammary tumors in dogs
By Jain, Mohit et al.·Published in Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology·2021·Mumbai Veterinary College, India·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: CEA, CA 15-3, and miRNA expression as potential biomarkers in canine mammary tumors.
- Species:
- dog
Plain-English summary
A group of dogs with mammary tumors was studied to find better ways to detect these tumors early. Researchers looked at certain cancer markers (CA 15-3 and CEA) and specific microRNAs (miR-21 and miR-29b) in the dogs' blood. They found that CA 15-3 was more sensitive than CEA for detecting tumors, and the levels of miR-21 and miR-29b changed significantly between healthy dogs and those with tumors. This means that testing for these markers could help vets diagnose mammary tumors in dogs earlier and more accurately, potentially improving treatment outcomes.
People also search for: dog mammary tumor symptoms · CA 15-3 test for dogs · miRNA biomarkers in canine cancer
Abstract
The most often detected tumor in intact bitches is mammary tumors and represents a significant clinical problem throughout the world. Mammary neoplasms in canine have heterogeneous morphology, so the choice of the most appropriate biomarker is the biggest challenge in CMT detection. We performed a retrospective analysis and evaluated the canine cancer antigens and miRNA expression profiles as potential biomarkers. Sixty dogs based on histological examination divided into three groups, viz., dogs with a benign mammary tumor, malignant mammary tumor, and control/healthy. The CA 15-3 was found more sensitive than CEA but detection of both will increase sensitivity. miR-21 expression differed significantly in all three groups. miR-29b expression differed significantly between the control and benign group and control and malignant group. The miR-21 overexpression and miR-29b downregulation with CMT are associated with clinical stage and can be used as non-invasive diagnostic and prognostic biomarkers. Hence, evaluation of CA 15-3 along with CEA would be a non-invasive technique for detecting canine mammary tumors. Evaluation of deregulated circulating miR-21 could be a valuable prognostic marker for early detection of mammary tumors in canines while miR-29b can add sensitivity in the detection of the canine mammary tumors if evaluated with miR-21.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33638118/